CY1109364T1 - Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες - Google Patents

Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες

Info

Publication number
CY1109364T1
CY1109364T1 CY20091100954T CY091100954T CY1109364T1 CY 1109364 T1 CY1109364 T1 CY 1109364T1 CY 20091100954 T CY20091100954 T CY 20091100954T CY 091100954 T CY091100954 T CY 091100954T CY 1109364 T1 CY1109364 T1 CY 1109364T1
Authority
CY
Cyprus
Prior art keywords
combination containing
cancer factors
combretastatin
containing combretastatin
cancer
Prior art date
Application number
CY20091100954T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1109364T1 publication Critical patent/CY1109364T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Παρέχεται ένα αντικαρκινικός συνδυασμός που περιλαμβάνει ένα παράγωγο στιλβίνης και μια αντικαρκινική ένωση που επιλέγεται από την ομάδα που αποτελείται από ταξάνες, αλκυλοποιητικούς παράγοντες, ατιμεταβολίτες, αλκαλοειδή vinca, επιδοφυλλοπτοξίνες, και αντιβιοτικά ως τα ενεργά συστατικά στοιχεία. Παρέχονται επίσης μέθοδοι χρήσης αυτών των φαρμακευτικών παρασκευασμάτων για τη θεραπεία των στερεών καρκινομάτων και άλλων παρόμοιων ασθενειών.
CY20091100954T 2001-03-15 2009-09-16 Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες CY1109364T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15
EP02732758A EP1439839B8 (en) 2001-03-15 2002-03-15 A combination comprising combretastatin and anticancer agents

Publications (1)

Publication Number Publication Date
CY1109364T1 true CY1109364T1 (el) 2014-07-02

Family

ID=23053164

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100954T CY1109364T1 (el) 2001-03-15 2009-09-16 Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες

Country Status (38)

Country Link
US (4) US20020183266A1 (el)
EP (1) EP1439839B8 (el)
JP (1) JP4991107B2 (el)
KR (1) KR100849610B1 (el)
CN (2) CN1290504C (el)
AR (1) AR032989A1 (el)
AT (1) ATE433750T1 (el)
AU (1) AU2002304574B2 (el)
BR (1) BR0208017A (el)
CA (2) CA2470484C (el)
CY (1) CY1109364T1 (el)
CZ (1) CZ302451B6 (el)
DE (1) DE60232673D1 (el)
DK (1) DK1439839T3 (el)
EA (1) EA006316B1 (el)
EC (1) ECSP034766A (el)
ES (1) ES2327617T3 (el)
HK (1) HK1067039A1 (el)
HR (1) HRPK20030734B3 (el)
HU (1) HU228510B1 (el)
IL (2) IL157891A0 (el)
MA (1) MA27000A1 (el)
ME (2) MEP16208A (el)
MX (1) MXPA03007552A (el)
NO (1) NO332661B1 (el)
NZ (1) NZ527526A (el)
PE (1) PE20020909A1 (el)
PL (1) PL205728B1 (el)
PT (1) PT1439839E (el)
RS (1) RS50682B (el)
SI (1) SI1439839T1 (el)
SK (1) SK287908B6 (el)
TN (1) TNSN03060A1 (el)
TW (1) TWI306028B (el)
UA (1) UA75127C2 (el)
UY (1) UY27208A1 (el)
WO (2) WO2002074229A2 (el)
ZA (1) ZA200306789B (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
ES2529434T3 (es) * 2007-11-21 2015-02-20 Oxigene, Inc. Método para tratar neoplasias hematopoyéticas
US20090209496A1 (en) * 2008-02-15 2009-08-20 David Chaplin Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
MX2012014732A (es) 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
JP2018523712A (ja) 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
DE69931766T2 (de) * 1998-04-03 2007-05-31 Ajinomoto Co., Inc. Antitumorale mittel
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
DE60031268T2 (de) * 1999-04-14 2007-05-24 Dana-Farber Cancer Institute, Inc., Boston Verfahren und zusammansetzung zur behandlung von krebs
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
AU2002216029B2 (en) * 2000-10-27 2006-01-05 Pfizer, Inc. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2002056692A1 (en) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
CN1935134A (zh) 2007-03-28
IL157891A (en) 2010-06-16
DE60232673D1 (de) 2009-07-30
MXPA03007552A (es) 2004-10-15
WO2004037258A1 (en) 2004-05-06
EP1439839B8 (en) 2010-09-01
NO20034022D0 (no) 2003-09-11
HUP0600233A3 (en) 2010-03-29
SK287908B6 (sk) 2012-03-02
ZA200306789B (en) 2005-02-23
PT1439839E (pt) 2009-09-03
YU71303A (sh) 2006-08-17
PL374406A1 (en) 2005-10-17
UA75127C2 (en) 2006-03-15
CZ302451B6 (cs) 2011-05-25
SI1439839T1 (sl) 2011-09-30
ECSP034766A (es) 2003-10-28
SK11552003A3 (sk) 2004-03-02
PE20020909A1 (es) 2002-12-09
AR032989A1 (es) 2003-12-03
HRP20030734A2 (en) 2005-06-30
US6933320B2 (en) 2005-08-23
US20020183266A1 (en) 2002-12-05
DK1439839T3 (da) 2009-10-05
US20070149476A1 (en) 2007-06-28
WO2002074229A2 (en) 2002-09-26
CA2470484C (en) 2009-10-13
NO20034022L (no) 2003-09-11
ATE433750T1 (de) 2009-07-15
BR0208017A (pt) 2004-12-07
EP1439839B1 (en) 2009-06-17
CN1290504C (zh) 2006-12-20
AU2002304574A1 (en) 2004-05-13
NO332661B1 (no) 2012-11-26
JP2005522527A (ja) 2005-07-28
HU228510B1 (en) 2013-03-28
TWI306028B (en) 2009-02-11
US20050075295A1 (en) 2005-04-07
CA2470484A1 (en) 2004-05-06
MEP16208A (en) 2010-06-10
EP1439839A1 (en) 2004-07-28
UY27208A1 (es) 2002-08-30
CA2673449A1 (en) 2004-05-06
KR20040067866A (ko) 2004-07-30
EA006316B1 (ru) 2005-10-27
MA27000A1 (fr) 2004-12-20
CN1547471A (zh) 2004-11-17
US20030060429A1 (en) 2003-03-27
KR100849610B1 (ko) 2008-07-31
IL157891A0 (en) 2004-03-28
ES2327617T3 (es) 2009-11-02
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
JP4991107B2 (ja) 2012-08-01
CZ20032476A3 (en) 2004-07-14
AU2002304574B2 (en) 2005-09-15
CN1935134B (zh) 2010-12-15
ME00056B (me) 2010-06-10
NZ527526A (en) 2006-11-30
EA200301015A1 (ru) 2004-08-26
HRPK20030734B3 (en) 2006-11-30
CA2673449C (en) 2011-10-18
TNSN03060A1 (en) 2005-12-23
HUP0600233A2 (en) 2008-06-30
HK1067039A1 (en) 2005-04-01

Similar Documents

Publication Publication Date Title
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
IS6658A (is) Ný efnasambönd
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
IS6329A (is) Lyf til að meðhöndla illkynja æxli
BR9810495A (pt) Composição farmacêutica
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
NO990833L (no) Farmas°ytiske forbindelser
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ATE233754T1 (de) Diphenyl-piperidin derivate
ATE405568T1 (de) Cytotoxische mittel
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
RU94040150A (ru) Стабильная лиофилизированная композиция тиотепа, способ ее получения
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
DE69626544T2 (de) Arzneistoffe
DE60214476D1 (de) Pharmazeutische Zubereitungen, Wirkstoffe enthaltend, die sich für unerlaubte Verabreichung anbieten
EA200500082A1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов